AstraZeneca's Epinova, an EPA and DHA formulation, was stopped in a trial due to futility.

“AstraZeneca had acquired a free omega-3 fatty acid meaning it's not an ethyl ester which means it has a better absorption better pharmacokinetics more bioavailability and it was called epinova but it was epa and dha but free epa and free dha and they enrolled basically the same type of people high triglycerides maybe the hdl cholesterol is low at-risk people and two years into the study the company just stopped the study it's never been published so we don't know but the reason was it's futility we're not seeing a signal at two years that it's gonna work so we're not wasting any more money on this”